Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
The Company's principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI.
Synthetic Biologics, Inc. is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome.
The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the effects of intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination for the treatment of Pertussis.
In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.
Discovery stage programs include a monoclonal antibody for the treatment of Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS.